Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Speckle tracking echocardiography

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Speckle tracking echocardiography. Displaying page 1 of 1.
    EudraCT Number: 2013-004368-74 Sponsor Protocol Number: OC5-OL-01 Start Date*: 2014-03-17
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase 2 open-label multi-centre study to evaluate the efficacy and safety of Oxabact® to reduce plasma oxalate in patients with primary hyperoxaluria who are on dialysis
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000240-17 Sponsor Protocol Number: ESTIMATE Start Date*: 2017-05-02
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes
    Medical condition: Coronary microvascular function in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 10007541 - Cardiac disorders 10072685 Microvascular coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003149-24 Sponsor Protocol Number: Ranolazine¿AOUPi/001 Start Date*: 2016-01-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Ranolazine in patients with post systolic thickening due to stable effort angina: a phase II, randomized, open-label, standard therapy controlled, parallel group study assessing the effects on left...
    Medical condition: Stable angina with normal ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004498-34 Sponsor Protocol Number: SUM Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodie...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000915-26 Sponsor Protocol Number: CMMo-OCC-2012 Start Date*: 2013-09-17
    Sponsor Name:FUNDACIÓN PROGRESO Y SALUD
    Full Title: Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and v...
    Medical condition: Chronic coronary occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011086 Coronary artery occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2008-005306-39 Sponsor Protocol Number: VitaminKStudy Start Date*: 2009-06-29
    Sponsor Name:RWTH Aachen University, represented by the rector, himself represented by Clinical Trial Center Aachen (CTC-A)
    Full Title: Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification
    Medical condition: progression of aortic valve calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10050559 Aortic valve calcification PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002153-35 Sponsor Protocol Number: GAP Start Date*: 2015-09-10
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Effect of Glucagon-like peptide-1 stimulation on coronary microvascular dysfunction in women with angina pectoris and no obstructive stenosis of major coronary vessels
    Medical condition: Patients with angina pectoris and coronary microvascular dysfunction without significant stenosis og major coronary vessels
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004433-24 Sponsor Protocol Number: 59498 Start Date*: 2017-05-17
    Sponsor Name:Leids Universitair Medisch Centrum
    Full Title: ACE inhibition in Fontan patients: its effect on body fluid regulation.
    Medical condition: Patients with univentricular hearts palliated by the Fontan procedure
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003576-12 Sponsor Protocol Number: OC5-OL-02 Start Date*: 2019-01-23
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: An open-label single-arm treatment extension study to evaluate the long-term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002270-12 Sponsor Protocol Number: TRIMETA Start Date*: 2016-10-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with br...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000914-23 Sponsor Protocol Number: SAFE2014 Start Date*: 2016-08-05
    Sponsor Name:DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE
    Full Title: Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: a randomized, placebo controlled, phase 3 trial - SAFE trial.
    Medical condition: Female, non metastatic histologically confirmed primary invasive breast cancer scheduled to receive neoadjuvant or adjuvant anthracyclines with or without anti Her 2 therapy, LVEF >50%
    Disease: Version SOC Term Classification Code Term Level
    20.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004490-17 Sponsor Protocol Number: 72 Start Date*: 2014-12-17
    Sponsor Name:Bipebjerg University Hospital
    Full Title: Effect of ACE-Inhibition on Microvascular Function in Women with Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease.
    Medical condition: Microvascular dysfunction/microvascular angina
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10065566 Microvascular angina LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000684-33 Sponsor Protocol Number: OC5-DB-02 Start Date*: 2017-06-06
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase III double-blind, randomized study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020702 Hyperoxalemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003273-42 Sponsor Protocol Number: 14AOI11 Start Date*: 2014-12-23
    Sponsor Name:CHU de Nice
    Full Title: Comparing a diuretic vascular filling in the initial management of acute pulmonary embolism with right ventricular dysfunction normotensive
    Medical condition: acute pulmonary embolism with right ventricular dysfunction normotensive
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10050071 Embolism lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000030-35 Sponsor Protocol Number: RIMINI-Pilot Start Date*: 2013-05-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial
    Medical condition: CAD with acute ischemia and myocardial dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028600 Myocardial ischaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020209-33 Sponsor Protocol Number: 07052010 Start Date*: 2010-10-12
    Sponsor Name:University Hospitals Leuven
    Full Title: BOsentan for Mild Pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial
    Medical condition: Repaired (after the age of 40) atrial septal defect patients older than 40 years with evidence of mild pulmonary vascular disese as assessed by bicycle stress echocardiography.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003664 Atrial septal defect LLT
    12.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002225-10 Sponsor Protocol Number: EMPA-HEART Start Date*: 2016-09-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Impact of empagliflozin on left ventricular functions: a single center, phase III, randomized, open-label, active treatment-controlled, parallel study in patients with type 2 diabetes and normal le...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005394-66 Sponsor Protocol Number: ESR-20-21070 Start Date*: 2022-02-21
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
    Full Title: Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction
    Medical condition: heart failure with left ventricular ejection fraction <50%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10024102 Left cardiac failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002834-59 Sponsor Protocol Number: SNFCT2015-05 Start Date*: 2016-11-28
    Sponsor Name:Sanifit Therapeutics S.A.
    Full Title: A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patie...
    Medical condition: Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10014646 End stage renal disease (ESRD) LLT
    20.0 10047065 - Vascular disorders 10051753 Vascular calcification PT
    20.0 10042613 - Surgical and medical procedures 10018875 Haemodialysis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 12:05:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA